secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rein Therapeutics, Inc. (RNTX)
CIK:        0001420565
Form:       8-K
Filed at:   2024-05-01T23:59:59+00:00
Accession:  0001193125-24-126425
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Aileron reports positive LTI-03 Phase 1b Cohort 1 IPF data; cash $12.0M
-----------------------------------------------------------------------

- 7 of 8 biomarkers showed positive trend; 3 statistically significant: GAL-7 (p=0.0014), TSLP (p=0.0223), Col-1α1 (p=0.0489).
- LTI-03 well-tolerated with no serious adverse events; solRAGE increased (p=0.1407), indicating type I epithelial cell health.
- Cohort 1: 12 patients (9 active, 3 placebo), inhaled 2.5 mg BID; cohort 2 high-dose results expected Q3 2024.
- Preliminary cash and cash equivalents ~$12.0M as of March 31, 2024, unaudited.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420565/000119312524126425/0001193125-24-126425-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420565/000119312524126425/d65915d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-126425

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer